

(12) PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. AU 199710277 B2
(10) Patent No. 725627

(54) Title
Reusable solid support for oligonucleotide synthesis, process for
production thereof and process for use thereof

(51)⁶ International Patent Classification(s)
C07H 021/00

(21) Application No: 199710277 (22) Application Date: 1996.12.13

(87) WIPO No: W097/23496

(30) Priority Data

(31) Number	(32) Date	(33) Country
60/009208	1995.12.22	US

(43) Publication Date : 1997.07.17
(43) Publication Journal Date : 1997.09.11
(44) Accepted Journal Date : 2000.10.19

(71) Applicant(s)
University Technologies International Inc.

(72) Inventor(s)
Richard T. Pon; Shuyuan Yu

(74) Agent/Attorney
DAVIES COLLISON CAVE,GPO Box 3876,SYDNEY NSW 2001

OPI DATE 17/07/97 APPLN. ID 10277/97
AOJP DATE 11/09/97 PCT NUMBER PCT/CA96/00836



AU9710277


PCT)

(51) International Patent Classification ⁶ : C07H 21/00		A1	(11) International Publication Number: WO 97/23496
			(43) International Publication Date: 3 July 1997 (03.07.97)
(21) International Application Number: PCT/CA96/00836		(81) Designated States: AU, CA, JP, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(22) International Filing Date: 13 December 1996 (13.12.96)			
(30) Priority Data: 60/009,208 22 December 1995 (22.12.95) US		Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	
(71) Applicant (for all designated States except US): UNIVERSITY TECHNOLOGIES INTERNATIONAL INC. [CA/CA]; Suite 204, 609 - 14 Street N.W., Calgary, Alberta T2N 2A1 (CA).			
(72) Inventors; and			
(75) Inventors/Applicants (for US only): PON, Richard, T. [CA/CA]; 108 Ranch Estates Road N.W., Calgary, Alberta T3G 2B4 (CA). YU, Shuyuan [CA/CA]; 53 Hawktree Circle N.W., Calgary, Alberta T3G 3M1 (CA).			
(74) Agents: NASSIF, Omar, A. et al.; McCarthy Téroult, Toronto Dominion Bank Tower, Suite 470, Toronto-Dominion Centre, Toronto, Ontario M5K 1E6 (CA).			

(54) Title: REUSABLE SOLID SUPPORT FOR OLIGONUCLEOTIDE SYNTHESIS, PROCESS FOR PRODUCTION THEREOF AND PROCESS FOR USE THEREOF

(57) Abstract

A solid support for oligonucleotide synthesis is disclosed. The solid support has formula (1) wherein: R⁸ is selected from the group consisting of a substituted or unsubstituted C₁-C₂₀ alkyl group, a substituted or unsubstituted C₅-C₃₀ aryl group and a substituted or unsubstituted C₅-C₄₀ alkylaryl group; X³ and X⁴ are the same or different and are selected from the group consisting of -O-, -S-, -S(O)₂- and -N(R¹²)-; R¹² is selected from the group consisting of a substituted or unsubstituted C₁-C₂₀ alkyl group, a substituted or unsubstituted C₅-C₃₀ aryl group and a substituted or unsubstituted C₅-C₄₀ alkylaryl group; and Y is selected from the group consisting of: -CH₂-CH₂-; -CH₂-CH₂-O-CH₂-; -CH₂-CH₂-CH₂-; -CH=CH-; -CH=C(CH₃)-; -C(CH₃)=C(CH₃)-; -CH₂-C(=CH₂)-; and -CH₂-S-CH₂-; wherein when Y is -CH₂-CH₂-, at least one of X³ and X⁴ is -O-. An aspect of the invention also relates to a linker arm for oligonucleotide synthesis based on the solid support. Process for producing of the solid support and the linker arm, respectively, are also disclosed. The linker arm is characterized by being reusable in an otherwise conventional oligonucleotide production protocol.



REUSABLE SOLID SUPPORT FOR OLIGONUCLEOTIDE
SYNTHESIS, PROCESS FOR PRODUCTION THEREOF AND
PROCESS FOR USE THEREOF

TECHNICAL FIELD

5 In one of its aspects, the present invention relates to a reusable solid support for oligonucleotide synthesis. In another of its aspects, the present invention relates to a process for production of such a reusable solid support. In yet another of its aspects, the present invention relates to a process for use of such a reusable solid support.

10

BACKGROUND ART

 The art of organic chemistry on solid supports is generally known. A useful review article on this topic may be found in "Organic Chemistry on Solid Supports" by Früchtel et al., *Angew. Chem. Int. Ed. Engl.*, **1996**, 35, pgs. 17-42,
15 the contents of which are hereby incorporated by reference.

 As discussed in Früchtel et al., the art has developed automated solid-phase synthesis of polypeptides, oligonucleotides and oligosaccharaides. Of particular interest here is solid-phase synthesis of oligonucleotides. The following are useful review articles/textbooks on this topic:

20 Beaucage et al., *Tetrahedron*, **1992**, 48, 2223;
 Davis et al., *Innovation and Perspectives in Solid Phase Synthesis*
 (Ed.: R. Epton), Intercept, Andover, **1992**, pg. 63;
 Montserra et al., *Tetrahedron*, **1994**, 50, 2617; and
 S. L. Beaucage et al., *Tetrahedron*, **1993**, 49, 6123-6194;
25 the contents of each of which are hereby incorporated by reference.

 In the solid-phase synthesis of oligonucleotides, it is known to synthesize the oligonucleotide on an inorganic solid support bearing a succinyl linker arm - see, for example, any of the following references:


30 Caruthers et al., *Genetic Engineering*, Plenum Press, New York
 (1982), Vol. 4, pgs. 1-17;
 Letsinger et al., *Genetic Engineering*, Plenum Press, New York
 (1985), Vol. 5, pg. 191;

-2-

Froehler et al., *Nucleic Acids Research*, 14:5399-5407 (1986); and
 Matteucci et al., *Journal of American Chemical Society*,
 103:3185-3186 (1981);

the contents of each of which are hereby incorporated by reference.


5 Typically, the succinyl linker arm has the following general formula:



Thus, the succinyl group links the growing oligonucleotide from its terminal 3' hydroxyl group by an ester bond to a primary amine on the support, which may be, for example, conventional controlled pore glass (CPG) or silica, by an amide bond. Once the desired oligonucleotide has been synthesized, it is freed or
 10 cleaved from the succinyl linker arm hydrolyzing the ester carbonyl group. The hydrolysis agent is usually concentrated ammonium hydroxide. Typically, this reaction can take from 1-4 hours to complete. With improvements to current solid-phase oligonucleotide synthesizers, this cleavage step can represent 50% or more of the total time require to synthesize the desired oligonucleotide.

15 Another type of linker arm is disclosed in United States patent 5,112,962 [Letsinger et al. (Letsinger)], the contents of which are hereby incorporated by reference. Letsinger teaches a linker arm for solid support synthesis of oligonucleotides and oligonucleotide derivatives have the following formula:

-3-



Thus, Letsinger teaches an oxalyl linker arm which purportedly release the synthesized oligonucleotide or oligonucleotide derivate in a period of 1-30 minutes in a manner that leaves the oligonucleotide fully protected. The oxalyl linker arm purportedly can be rapidly cleaved by 5% ammonium hydroxide in methanol, ammonium hydroxide, wet tertiary amine, triethylamine/alcohol, triethylamine/methanol, triethylamine/ethanol, aqueous trimethylamine and other bases. Unfortunately, the oxalyl linker arm of Letsinger suffers from its purported advantage. Specifically, the present inventors have discovered that the oxalyl linker arm of Letsinger is susceptible to significant spontaneous hydrolysis (e.g. spontaneous hydrolysis of ~10-40% per month) which renders it difficult to use in commercial operations. The oxalyl arm is also difficult to prepare because it requires using oxalyl chloride, which is highly reactive, toxic and therefore dangerous.

Regardless of the specific nature of the linker arm, it is generally accepted in the art that the linker arm is not reusable after production and cleavage of the desired oligonucleotide. Thus, conventional linker arms may be regarded as non-recyclable. This is illustrated in Figure 1 which illustrates the conventional use of a succinyl linker arm for the production of an oligonucleotide. Thus, as illustrated, after cleavage of the desired oligonucleotide, the support is irreversibly linked to the linker compound (i.e. the succinyl moiety) and cannot be reused.

-4-

The art is in need of a linker arm for solid support oligonucleotide synthesis, which linker arm is recyclable. More specifically, the art is in need of a linker arm capable of repeated oligonucleotide synthesis/cleavage.

5 DISCLOSURE OF THE INVENTION


It is an object of the present invention to provide a novel solid support for oligonucleotide synthesis which obviates or mitigates at least one of the above-mentioned disadvantages of the prior art.

It is another object of the present invention to provide a novel process for
10 producing the solid support.

It is an object of the present invention provide a novel linker arm for solid support oligonucleotide synthesis which obviates or mitigates at least one of the above-mentioned disadvantages of the prior art.

It is another object of the present invention to provide a novel process for
15 producing a linker arm for solid support oligonucleotide synthesis.

Accordingly, in one of its aspects, the present invention provides a solid support for oligonucleotide synthesis, the solid support having the following formula:



20 wherein: R^8 is selected from the group consisting of a substituted or unsubstituted C_1 - C_{20} alkyl group, a substituted or unsubstituted C_5 - C_{30} aryl group and a substituted or unsubstituted C_5 - C_{40} alkylaryl group; X^3 and X^4 are the same or different and are selected from the group consisting of -O-, -S-, -S(O)₂- and -N(R^{12})-; R^{12} is selected from the group consisting of a substituted or
25 unsubstituted C_1 - C_{20} alkyl group, a substituted or unsubstituted C_5 - C_{30} aryl group


-5-

and a substituted or unsubstituted C₅-C₄₀ alkylaryl group; and Y is selected from the group consisting of:

- 5
- | | |
|--|---|
| -CH ₂ -CH ₂ -; | -CH ₂ -; |
| -CH ₂ -O-CH ₂ -; | -CH ₂ -CH ₂ -CH ₂ -; |
| -CH=CH-; | -CH=C(CH ₃)-; |
| -C(CH ₃)=C(CH ₃)-; | -CH ₂ -C(=CH ₂)-; and |
| -CH ₂ -S-CH ₂ -; | |

- 10 wherein when Y is -CH₂-CH₂-, at least one of X³ and X⁴ is -O-.


In another of its aspects, the present invention provides a process for production of a solid support for oligonucleotide synthesis, the solid support having the following formula:




- 15 wherein: R⁸ is selected from the group consisting of a substituted or unsubstituted C₁-C₂₀ alkyl group, a substituted or unsubstituted C₅-C₃₀ aryl group and a substituted or unsubstituted C₅-C₄₀ alkylaryl group; X³ and X⁴ are the same or differed and are selected from the group consisting of -O-, -S-, -S(O)₂- and -N(R¹²)-; R¹² is selected from the group consisting of a substituted or
- 20 unsubstituted C₁-C₂₀ alkyl group, a substituted or unsubstituted C₅-C₃₀ aryl group and a substituted or unsubstituted C₅-C₄₀ alkylaryl group; and Y is selected from the group consisting of:

- 25
- | | |
|--|---|
| -CH ₂ -CH ₂ -; | -CH ₂ -; |
| -CH ₂ -O-CH ₂ -; | -CH ₂ -CH ₂ -CH ₂ -; |

-6-




- 5 wherein when Y is $-\text{CH}_2-\text{CH}_2-$, at least one of X^3 and X^4 is $-\text{O}-$;
 the process comprising the step of reacting together the compounds of
 Formulae I, II and III:




wherein R^8 , X^3 , X^4 and Y are as defined above.

- In yet another of its aspects, the present invention provides a linker arm
 10 for solid support oligonucleotide synthesis, the linker arm comprising the
 following formula:



- wherein: R^8 is selected from the group consisting of a substituted or
 unsubstituted C_1-C_{20} alkyl group, a substituted or unsubstituted C_5-C_{30} aryl group
 and a substituted or unsubstituted C_5-C_{40} alkylaryl group; X^3 and X^4 are the same
 15 or different and are selected from the group consisting of $-\text{O}-$, $-\text{S}-$, $-\text{S}(\text{O})_2-$ and
 $-\text{N}(\text{R}^{12})-$; R^{12} is selected from the group consisting of a substituted or
 unsubstituted C_1-C_{20} alkyl group, a substituted or unsubstituted C_5-C_{30} aryl group
 and a substituted or unsubstituted C_5-C_{40} alkylaryl group; Y is selected from the
 group consisting of:

-7-




5

and Z is a linker moiety; wherein when Y is $-\text{CH}_2-\text{CH}_2-$, at least one of X^3 and X^4 is $-\text{O}-$.

In yet another of its aspects, the present invention provides a process for producing a linker arm for solid support oligonucleotide synthesis, the linker arm comprising the following formula:


10



wherein: R^8 is selected from the group consisting of a substituted or unsubstituted C_1-C_{20} alkyl group, a substituted or unsubstituted C_5-C_{30} aryl group and a substituted or unsubstituted C_5-C_{40} alkylaryl group; X^3 and X^4 are the same or different and are selected from the group consisting of $-\text{O}-$, $-\text{S}-$, $-\text{S}(\text{O})_2-$ and $-\text{N}(\text{R}^{12})-$; R^{12} is selected from the group consisting of a substituted or unsubstituted C_1-C_{20} alkyl group, a substituted or unsubstituted C_5-C_{30} aryl group and a substituted or unsubstituted C_5-C_{40} alkylaryl group; Y is selected from the group consisting of:

15

20



25


-8-

and Z is a linker moiety; wherein when Y is $-\text{CH}_2-\text{CH}_2-$, at least one of X^3 and X^4 is $-\text{O}-$;


the process comprising the step of reacting together the compounds of Formulae IV, V and VI:



(IV)



(V)



(VI)

5 wherein R^8 , X^3 , X^4 , Y and Z are as defined above.

As used throughout this specification, the term "oligonucleotide" is intended to have a broad meaning and encompasses conventional oligonucleotides, backbone-modified oligonucleotides (e.g. phosphorothioate, phosphorodithioate and methyl-phosphonate analogs useful as oligotherapeutic
10 agents) and oligonucleotide derivatives such as oligonucleotide-peptide conjugates.

Throughout this specification, when reference is made to a substituted moiety, the nature of the substitution is not specification restricted and may be selected from the group consisting of a C_1 - C_{20} alkyl groups, a C_5 - C_{30} aryl group a
15 C_5 - C_{40} alkaryl group.

BRIEF DESCRIPTION OF THE DRAWINGS

Embodiments of the present invention will be described with reference to the accompany drawing in which:

20 Figure 1 illustrates a specific process pathway for conventional oligonucleotide synthesis; and

Figure 2 illustrates a specific preferred embodiment of the present invention.

BEST MODE FOR CARRYING OUT THE INVENTION

5 Initially, to facilitate an understanding of the invention, reference will be made to Figure 1, which illustrates a conventional process for solid support oligonucleotide synthesis.

Thus, the initial step of the process illustrated in Figure 1 comprises reacting a linking compound, such as succinic acid (while succinic acid is
10 illustrated, succinic anhydride may also be used), with a conventional amine-terminated support. The reaction results in the formation of an amide linkage between the linking compound and the support to produce succinyl-support conjugate.

Next, the succinyl-support conjugate is reacted with a desired initial
15 nucleoside to produce a linker arm. In the illustrated nucleoside, DMT is dimethoxytrityl, B is the nucleobase and R' is H (for deoxyribonucleosides) or OR (for ribonucleosides) wherein R is H or a conventional blocking/ protecting group. The reaction results in the formation of an ester linkage between the linking compound and the desired initial nucleoside at the 3' position of the latter.

20 The linker arm is then used in conventional oligonucleotide synthesis (e.g. in a conventional automated synthesizer) to produce an oligonucleotide of desired sequence attached to the linker arm.

The oligonucleotide is then cleaved from the linker by hydrolysis. This serves to cleave the ester bond thereby freeing the oligonucleotide and an amine-
25 terminated, non-reusable linker arm.


The present inventors have discovered that derivatization of a conventional support to provide a unique hydroxy-terminated functionality and then reacting this derivatized support with a conventional linking compound leads to production of a linker arm which may used to synthesize an oligonucleotide of
30 desired sequence. A key feature of the invention is then the derivated support may be regenerated after cleavage of the oligonucleotide of desired sequence. To the

-10-

inventors' knowledge, this is the first discovery of a derivatized support which may be used repeatedly in oligonucleotide synthesis.

The derivatized support of the present invention has the following formula:

5



wherein: R^8 is selected from the group consisting of a substituted or unsubstituted $\text{C}_1\text{-C}_{20}$ alkyl group, a substituted or unsubstituted $\text{C}_5\text{-C}_{30}$ aryl group and a substituted or unsubstituted $\text{C}_5\text{-C}_{40}$ alkylaryl group; X^3 and X^4 are the same or different and are selected from the group consisting of -O-, -S-, -S(O)₂- and -N(R¹²)-; R^{12} is selected from the group consisting of a substituted or unsubstituted $\text{C}_1\text{-C}_{20}$ alkyl group, a substituted or unsubstituted $\text{C}_5\text{-C}_{30}$ aryl group and a substituted or unsubstituted $\text{C}_5\text{-C}_{40}$ alkylaryl group; and Y is selected from the group consisting of:

15 -CH₂-CH₂-; -CH₂-;
 -CH₂-O-CH₂-; -CH₂-CH₂-CH₂-;
 -CH=CH-; -CH=C(CH₃)-;
 -C(CH₃)=C(CH₃)-; -CH₂-C(=CH₂)-; and
 -CH₂-S-CH₂-;

20

wherein when Y is -CH₂-CH₂-, at least one of X^3 and X^4 is -O-.


Preferably, R^8 is a substituted or unsubstituted $\text{C}_1\text{-C}_{20}$ alkyl group, more preferably a substituted or unsubstituted $\text{C}_1\text{-C}_{10}$ alkyl group, most preferably a member selected from the group consisting of ethyl, *n*-propyl, *n*-butyl, *n*-pentyl
 25 and *n*-hexyl. Preferably, R^{12} is hydrogen.

-11-

Preferably, X^3 and X^4 are both $-N(H)-$. Also, preferably, Y is $-CH_2-CH_2-$.

The SUPPORT in the above formula is a conventional solid support. The nature of the solid support is not particularly restricted and is within the purview of a person skilled in the art. Thus, the solid support may be an inorganic substance. Non-limiting examples of suitable inorganic substances may be selected from the group consisting of silica, porous glass, aluminosilicates, borosilicates, metal oxides (e.g. aluminum oxide, iron oxide, nickel oxide) and clay containing one or more of these. Alternatively, the solid support may be an organic substance such as a cross-linked polymer. Non-limiting examples of a suitable cross-linked polymer may be selected from the group consisting of polyamide, polyether, polystyrene and mixtures thereof. The preferred solid support for use herein is conventional and may be selected from controlled pore glass bead or polystyrene beads.

The derivatized support of the present invention may be produced by a process comprising the step of reacting together compounds of the Formulae I, II and III:




wherein R^5 , X^3 , X^4 and Y are as defined above. The discussion above with respect to preferred embodiments of R^5 , X^3 , X^4 and Y in the derivatized support applies equally here to the discussion of the process for producing the derivatized support.

The reaction of acid anhydride of Formula II with either the compound of Formula I or the compound of Formula III needs no special activation. Attachment of the remaining compound to the combination of Formulae I and II, or Formula II and III, may be performed by activation of the carboxylic acid function by conventional means, for example by use of the activating agents

-12-

discussed in more detail hereinbelow. Preferably, the compounds of Formulae II and III are combined first in the presence of a catalytic agent (e.g. 4-dimethylaminopyridine (DMAP)) in anhydrous pyridine. Then the compound of Formula I is attached using a carbodiimide reagent (e.g., 1-(3-dimethylaminopropyl)-ethylcarbodiimide (DEC)) and an acylation catalyst (e.g. DMAP) in an organic solvent (e.g. dichloromethane).


The derivatized supported may then be reacted with a conventional nucleoside-linker compound to produce the linker arm according to the present invention. This linker arm has the following formula:



10

wherein R^8 , X^3 , X^4 and Y are as defined above and Z is a linker moiety. The discussion above with respect to preferred embodiments of R^8 , X^3 , X^4 and Y in the derivatized support and process for production thereof applies equally here to the discussion of linker arm based on the derivatized support. Preferably, in the above formula, NUCLEOSIDE is a moiety selected from one of the following formulae:

15



wherein R^8 and R^{10} are the same or different and are hydrogen or a protecting group, R^9 is hydrogen (for deoxyribonucleosides or DNA) or $-OR^{11}$ (for ribonucleosides or RNA) wherein R^{11} is hydrogen or a protecting group, and B^* a nucleic acid base. Thus, in the case of RNA, there are two hydroxyl groups which may be protected. Also, the linker can be attached to either the 5'-, 3'- or (if ribose) 2'- hydroxyl positions. Indeed, for RNA sequences, it makes little difference whether the ester linker formed between the nucleoside and the linker compound is at the 2'- or 3'- hydroxyl position of the nucleoside. Thus, those of skill in the art will recognize that the nucleoside may be protected or blocked at the various of its hydroxyl moieties.

Non-limiting examples of useful protecting groups may be selected from the group consisting of trityl, methoxytrityl, dimethoxytrityl (DMT), dialkylphosphite, pivalyl-isobutyloxycarbonyl, *t*-butyldimethylsilyl, phenoxyacetal, 9-phenylxanthene-9-yl (pixyl), tetrahydropyranyl, methoxytetrahydropyranyl, methoxymethyl, benzyloxymethyl, methoxyethoxymethyl, methylthiomethyl, dialkylphosphate, levulinyl, dimethylphenylsilyl, trimethylsilyl, isopropylidimethylsilyl,

-14-

diisopropylmethylsilyl, diethylisopropylsilyl, triisopropylsilyl, acetyl, benzoyl, pivaloyl, trifluoroacetyl, allyl, benzyl, o-nitrobenzyl, o-hydroxystyryldimethylsilyl, 2-oxo-1,2-diphenylethyl, allyloxycarbonyl, monomethoxymethyl, nitroveratryloxycarbonyl, dimethoxybenzoin, 5 dimethoxybenzoin carbonate, methylnitropiperonyl carbonate, fluorenyl-methoxycarbonyl, 2-phenylsulfonylethoxycarbonyl, fluorophenyl-methoxypiperidinyl and the like.

As is known in the art, the main prerequisite for the protecting group used on the 5'-hydroxyl position is its ability to be selectively removed without causing 10 cleavage of the linker arm. Thus, the preferred protecting group for desired 5'-hydroxyl position(s) is the acid labile dimethoxytrityl group. The main prerequisite for protecting groups on other hydroxyl positions, is stability to the conditions used for removal of the above protecting group. These latter protecting groups may be removed by the same conditions used to cleave the linker 15 (discussed below) or separate conditions. The preferred protecting groups for these positions are trialkylsilyl (i.e. t-butyldimethylsilyl) or acetyl. Additional information may be obtained from the following references:

- 20 1. T. W. Greene and P. G. M. Nuts, "Protecting Groups in Organic Synthesis", Second Edition (1991), John Wiley and Sons, Inc., NY;
2. M. Schelhaas and H. Waldman, "Protecting Group Strategies in Organic Synthesis", Angew. Chemie Int. Ed. Engl. **35**, 2056-2083 (1996);
- 25 3. M. J. Gait, ed., "Oligonucleotide Synthesis A Practical Approach", IRL Press, Oxford (1984);
4. S. A. Narang, ed., "Synthesis and Applications of DNA and RNA", Academic Press, Inc., Orlando (1987); and
- 30 5. S. Agrawal, ed., "Methods in Molecular Biology, Vol. 20: Protocols for Oligonucleotides and Analogs", Humana Press, Totowa, NJ (1993);

the contents of each of which are hereby incorporated by reference, for a discussion of other possible hydroxyl protecting groups.

The manner by which the desired nucleoside may be protected is
5 conventional and within the purview of a person skilled in the art. See, for example United States patent 3,400,190 (Melby), United States patent 4,458,066 (Caruthers et al.), the contents of each of which are hereby incorporated by reference.


A preferred method for production of deoxyribonucleosides in the context
10 of the present invention is to use a nucleoside with a 5'-dimethoxytrityl protecting group and an appropriate exocyclic amino protecting group, e.g., N⁶-benzoyl-5'-dimethoxytrityl-2'-deoxyadenosine, N⁴-benzoyl-5'-dimethoxytrityl-2'-deoxycytidine, 5'-dimethoxytrityl-N²-isobutyryl-2'-deoxyguanosine, or 5'-dimethoxytritylthymidine.

A preferred method for production of ribonucleosides in the context of the
15 present invention is to use a 5'-dimethoxytrityl protected nucleoside, with appropriate exocyclic amino protection, and no protecting groups on either of the 2'- or 3'-hydroxyl positions. The linker can then react with either one of the two adjacent hydroxyl groups (it doesn't matter which) to give a mixture of 2'- and 3'-
20 linkages. The unreacted hydroxyl groups may then be acetylated by treatment of the immobilized nucleoside with acetic anhydride. Alternatively, ribonucleosides which have a 5'-dimethoxytrityl group, appropriate exocyclic amino group protection, and either a 3'-hydroxyl protecting group or a mixture of 2'- and 3'-protecting groups can be used. The 3'-protected compounds are generally
25 unwanted isomers which are simultaneously produced when the 2'-hydroxyl position is protected and having little other use.

In the above formula for the present linker arm, Z is a linker moiety. As
will be discussed below, Z is derived from a linker compound have the general
formula HO-Z-OH (Formula V below). The nature of the linker compound is not
30 particularly restricted.


In one preferred embodiment, linker moiety Z has the formula:

-16-



As will be apparent to those of skill in the art, this linker moiety may be derived from succinic acid or succinic anhydride.

In another preferred embodiment, linker moiety Z has the following formula:




5

As will be apparent to those of skill in the art, this linker moiety may be derived from diglycolic acid or diglycolic anhydride.

In yet another preferred embodiment, linker moiety Z has the following formula:

10




-17-


As will be apparent to those of skill in the art, this linker moiety may be derived from oxalic acid or oxalyl chloride.

In yet another, and most, preferred embodiment, linker moiety Z has the following formula:

5




wherein: R^1 , R^2 and R^3 are the same or different and are selected from the group consisting of hydrogen, halide, a substituted or unsubstituted $\text{C}_1\text{--C}_{20}$ alkyl group, a substituted or unsubstituted $\text{C}_5\text{--C}_{30}$ aryl group and a substituted or unsubstituted $\text{C}_5\text{--C}_{40}$ alkylaryl group; R^4 and R^5 are the same or different and are selected from the group consisting of hydrogen, a substituted or unsubstituted $\text{C}_1\text{--C}_{20}$ alkyl group, a substituted or unsubstituted $\text{C}_5\text{--C}_{30}$ aryl group and a substituted or unsubstituted $\text{C}_5\text{--C}_{40}$ alkylaryl group; X^1 is selected from the group consisting of ---O--- , ---C(O)--- , ---S--- , $\text{---S(O)}_2\text{---}$ and ---N(R)--- ; R is selected hydrogen, a substituted or unsubstituted $\text{C}_1\text{--C}_{20}$ alkyl group, a substituted or unsubstituted $\text{C}_5\text{--C}_{30}$ aryl group and a substituted or unsubstituted $\text{C}_5\text{--C}_{40}$ alkylaryl group; n is 0, 1 or 2; and one of A^1 and B^1 is selected from the group consisting of hydrogen, halide, a substituted or unsubstituted $\text{C}_1\text{--C}_{20}$ alkyl group, a substituted or unsubstituted $\text{C}_5\text{--C}_{30}$ aryl group and a substituted or unsubstituted $\text{C}_5\text{--C}_{40}$ alkylaryl group, and the other of A^1 and B^1 has the formula:



- wherein p is 0 or 1, X² is selected from the group consisting of -O-, -S-, -C(O)-, -S(O)₂- and -N(R)-, R is selected from the group comprising hydrogen, a substituted or unsubstituted C₁-C₂₀ alkyl group, a substituted or unsubstituted C₅-C₃₀ aryl group and a substituted or unsubstituted C₅-C₄₀ alkylaryl group, R⁶ and R⁷ are the same or different and are selected from the group consisting of a substituted or unsubstituted C₁-C₂₀ alkyl group, a substituted or unsubstituted C₅-C₃₀ aryl group and a substituted or unsubstituted C₅-C₄₀ alkylaryl group, and m is 0, 1 or 2. In this embodiment, B¹ preferably is selected from the group consisting of hydrogen, halide, a substituted or unsubstituted C₁-C₂₀ alkyl group, a substituted or unsubstituted C₅-C₃₀ aryl group and a substituted or unsubstituted C₅-C₄₀ alkylaryl group. Preferably, at least one, more preferably each, of R, R⁴, R⁵, R⁶ and R⁷ is hydrogen and preferably at least, more preferably both, of m and n are 1. It is further preferred that each of R¹, R² and R³ is hydrogen and that X¹ and X² are both -O-. Thus, in this embodiment, the most preferred form of linker moiety Z is derived from hydroquinone-O,O'-diacetic acid.

In yet another preferred embodiment, linker moiety Z has the following formula:




-19-

- wherein R^4 , R^5 , R^6 and R^7 are the same or different and are selected from the group consisting of hydrogen, a substituted or unsubstituted C_1 - C_{20} alkyl group, a substituted or unsubstituted C_5 - C_{30} aryl group and a substituted or unsubstituted C_5 - C_{40} alkylaryl group, Y is selected from the group consisting of O, S, SO_2 and
- 5 O- $((CH_2)_l-O)_q$, l is an integer less than or equal to 60, q is an integer in the range of 1-1000, n and m are the same or different and are 1 or 2, with the proviso that, when Y is O, at least one of n and m is 2. Preferably, l is an integer in the range of 1-10, and q is an integer in the range of 1-1000. In this embodiment, the most preferred form of linker moiety Z is derived from thiodiglycolic acid (i.e. $R^4=R^5=R^6=R^7=H$, $n=m=1$ and $Y=S$).
- 10


The present linker arm may be produced by a process comprising the step of reacting together the compounds of Formulae IV, V and VI:



(IV)



(V)



(VI)

- wherein R^8 , X^3 , X^4 , Y and Z are as defined above. The discussion above with respect to preferred embodiments of R^8 , X^3 , X^4 , Y and Z in respect of the linker
- 15 arm of the present invention applies equally here to the discussion of the process to produce linker arm.

- The compounds of Formulae IV, V and VI are preferably reacted in the presence of an activating agent. As used throughout this specification, the term "activating group" is intended to have a broad meaning and is intended to
- 20 encompass electrophilic reagents capable of activating a carboxyl moiety (e.g. on the linking compound of Formula V) by attachment of a leaving group to the acyl

-20-

carbon of the carboxyl moiety - see, for example, M. Bodanszky, "Principles of Peptide Synthesis", Second Edition, Springer-Verlag, Berlin (1993), the contents of which are hereby incorporated by reference. Thus, the activating agent should be capable of initiating at least one of the following: (a) formation of a reactive acylating agent (this is an example of a derivative) from the carboxyl moiety in a separate step or steps, followed by immediate treatment with the amino component (in this case, for example, an amino-terminated support) to form an amide linkage or a hydroxy component (in this case a hydroxy-terminated support or a hydroxyl group on the desired nucleoside) to form an ester linkage; (b) formation of an isolable acylating agent, separately, optionally with purification prior to treatment with the amino or hydroxy component as discussed in (a); and (c) formation of an acylating intermediate in the presence of the amino/hydroxy component, by the addition of an activating agent to a mixture of the two components. Thus, each of (a), (b) and (c) are applicable to the formation of both carboxylic esters and amides and all three routes can be used to attach nucleosides to supports.

For example, the Letsinger method, which first reacts oxalyl chloride with triazole, and then adds a nucleoside to the resulting oxalyl triazolide is an example of route (a). Conversion of the carboxylic acid group into an "active" ester using either p-nitrophenol, or di-, tri-, tetra-, or penta- chlorinated or fluorinated phenols, or N-hydroxysuccinimide are common examples of route (b). Route (c) has been the most commonly used method in recent years and both the carbodiimide reagents (dicyclohexylcarbodiimide, 1-(3-dimethylaminopropyl)-ethylcarbodiimide, and diisopropylcarbodiimide) and uronium reagents (O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU), 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate, (HBTU)) may be used in this approach.

In a preferred embodiment, in addition to an activating reagent, the reaction of the compounds of Formula (IV), (V) and (VI) is conducted in the presence of a nucleophilic catalyst or additive (typically 4-dimethylamino pyridine (DMAP), 1-hydroxybenzotriazole (HOBt), or 1-hydroxy-7-

-21-

azabenzotriazole (HOAt)) to speed up the reaction and a tertiary amine base (typically triethylamine, pyridine, or diisopropylethylamine) to ionize the carboxylic acid group.

Thus, those of skill in the art will recognize that the precise nature of the activation agent is not particularly restricted provided, of course, that the activated carboxylic acid group is capable of initiating formation of the ester or amide linkage, as appropriate, and the activating reagent does not have any deleterious effect on the desired nucleoside.

Thus activation of the carboxylic acid by conversion into an acid chloride; an active ester (i.e. nitrophenyl, nitrophenylthio, trichlorophenyl, trifluorophenyl, pentachlorophenyl, pentafluorophenyl, or 3-hydroxy-2,3-dihydro-4-oxo-benzotriazine esters); an active hydroxylamine ester (i.e. N-hydroxyphthalimide or N-hydroxysuccinimide); acid anhydride; or mixed anhydride will produce derivatives which will form the desired linkage, and thus, these strategies are encompassed herein.

Non-limiting examples of activating agents may be selected from the group consisting of arylsulfonyl chlorides (e.g. benzenesulfonyl chloride (BS-Cl), mesitylenesulfonyl chloride (MS-Cl), triisopropylsulfonylchloride (TPS-Cl)); active arylsulfonyl esters (i.e. imidazole, triazole, nitrotriazole, or tetrazole esters of BS-Cl, MS-Cl or TPS-Cl); 2-ethoxy-1-(ethoxycarbonyl)-1,2-dihydroquinoline (EEDQ); acyl carbonates; 1,1'-(carbonyldioxy)dibenzotriazoles; chlorotrimethylsilane; carbodiimides (i.e. dicyclohexylcarbodiimide (DCC), 1-(3-dimethylaminopropyl)-ethylcarbodiimide(DEC), diisopropylcarbodiimide(DIC)) either alone or in combination with auxillary nucleophiles (i.e. 1-hydroxybenzotriazole (HOBt), 1-hydroxy-7-azabenzotriazole (HOAt), N-hydroxysuccinimide (HOSu), or 3-hydroxy-3,4-dihydro-1,2,3-benzotriazin-4-one (HOObt)) and/or catalysts (i.e. 4-dimethylaminopyridine (DMAP) or N-methylimidazole (NMI)); or uronium salts (i.e. tetramethyluronium chloride (TMU-Cl), 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU), 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (TBTU), 2-succinimido-1,1,3,3-

tetramethyluronium tetrafluoroborate (TSTU), 2-(3,4-dihydro-4-oxo-1,2,3-benzotriazin-3-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (TDBTU), 2-(2-oxo-1(2H)-pyridyl-1,1,3,3-tetramethyluronium tetrafluoroborate (TPTU), 2-(5-norbornene-2,3-dicarboximido)-1,1,3,3-tetramethyluronium tetrafluoroborate
 5 (TNTU), O-(7-azabenzotriazol-1-yl)-1,3-dimethyl-1,3-dimethylenuronium hexafluorophosphate (HAMDU), O-(7-azabenzotriazol-1-yl)-1,3-dimethyl-1,3-trimethylenuronium hexafluorophosphate (HAMTU), O-(7-azabenzotriazol-1-yl)-1,1,3,3-bis(pentamethylene)uronium hexafluorophosphate (HAPipU), O-(7-azabenzotriazol-1-yl)-1,1,3,3-bis(tetramethylene)uronium hexafluorophosphate
 10 (HAPyU), O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU)) either alone or in combination with auxillary nucleophiles (i.e. 1-hydroxybenzotriazole (HOBt), 1-hydroxy-7-azabenzotriazole (HOAt), N-hydroxysuccinimide (HOSu), or 3-hydroxy-3,4-dihydro-1,2,3-benzotriazin-4-one (HOOBt)) and/or catalysts (e.g. 4-dimethylaminopyridine
 15 (DMAP) or N-methylimidazole (NMI)) or phosphonium salts (e.g. benzotriazol-1-yl-oxytris(dimethylamino)phosphonium hexafluorophosphate (BOP), benzotriazole-1-yl-oxy-trispyrrolidinophosphonium hexafluorophosphate (PyBOP), 2-(benzotriazol-1-yl)oxy-1,3-dimethylimidazolidinium hexafluorophosphate (BOI), bromo tris(pyrrolidino)phosphonium
 20 hexafluorophosphate (PyBroP), 7-azabenzotriazol-1-yloxytris-(dimethylamino)phosphonium hexafluorophosphate (AOP), and 7-azabenzotriazol-1-yloxytris(pyrrolidino)phosphonium hexafluorophosphate (PyAOP)) either alone or in combination with auxillary nucleophiles and/or catalysts (discussed above) will also produce the desired linkage.

25 Other examples of suitable activating reagents may be found in any of the following references:

- M. Bodanszky, "Principles of Peptide Synthesis", Second Edition, Springer-Verlag, Berlin (1993);
 30 J. Jones, "Amino Acid and Peptide Synthesis", Oxford University Press, Oxford (1992);

-23-

G. Grant, "Synthetic Peptides: A Users Guide", W. H. Freeman & Co., NY (1992);
E. Haslam, Tetrahedron, **36**, pg. 2409, (1980); and
M. A. Ogliaruso and J. F. Wolfe, "Synthesis of Carboxylic Acids,
5 Esters and Their Derivatives", John Wiley & Sons, Chicester (1991);

the contents of each of which are hereby incorporated by reference.

10 In producing the present linker arm, the order of reaction is not particularly restricted. Thus, in one embodiment (this is the preferred embodiment), the compounds of Formulae IV and V are initially reacted to form a conjugate which is reacted with the compound of Formula VI. In another embodiment, the compounds of Formulae V and VI are initially reacted to form a conjugate which is reacted with the compound of Formula IV.

15 The addition of compounds of Formulae IV and V to Formula VI, usually will not result in the quantitative conversion of each immobilized hydroxyl group into a derivatized ligand. Therefore, it is preferred that unreacted hydroxyl groups on the surface of the support be protected (capped) by reaction with a capping reagent. This will mitigate the free hydroxyl group participating in subsequent
20 oligonucleotide chain extension reactions, resulting in defect sequences lacking the terminal nucleoside. Preferably, the capping reagent should be reversible so that the capping agent can be removed to regenerate the hydroxyl sites prior to the next round of support derivatization. Capping of the unreacted sites is conventional and can be performed by reaction with an activated carboxylic acid
25 or anhydride to form an ester, or by addition of a protecting group, as described hereinabove. Thus, for example, *t*-butylphenoxyacetic anhydride or preferably chloroacetic anhydride in 2,6-lutidine/THF solution combined with an equal volume of N-methylimidazole in THF solution are useful examples of capping reagents.

30 With reference to Figure 2, there is illustrated a preferred reaction pathway for various embodiments of the invention. For clarity, the unreacted

-24-

linker sites and the subsequent addition and removal of the capping groups is not shown in Figure 2. In Figure 2, DMT refers to dimethoxytrityl; B^{*} refers to a nucleobase and R¹⁰ is as described hereinabove. As will be apparent to those of skill in the art, the support is recycled after oligonucleotide cleavage and support
5 regeneration to a point in the reaction scheme where it may again be coupled with the HQPD-nucleoside conjugate for further oligonucleotide synthesis.

With further reference to "oligonucleotide synthesis" in Figure 2, once the present linker arm has been produced, it may be used in the conventional manner to synthesize an oligonucleotide - see, for example, United States patent
10 5,112,962 (Letsinger), incorporated by reference hereinabove. Once the oligonucleotide has been synthesized, it may be cleaved from the solid support to yield the free oligonucleotide and the support may then be regenerated - see Figure 2.

The cleavage step comprises hydrolysis at the point of attachment of the
15 initial nucleoside to the linking compound. The regeneration of the support involves the removal of two moieties: (i) the removal of the structure represented by Formula V (above) from Formula VI (above), which occurs simultaneously with the release of the oligonucleotide product, and (ii) the removal of the moiety used to protect (cap) unreacted hydroxyl sites of Formula
20 VI (above) on the support. Removal of these two moieties can occur simultaneously or separately to regenerate the support. Simultaneous removal of both moieties using only a single reagent is simpler but care should be taken to use reagents which will not deleteriously affect the oligonucleotide product. A
25 two-step regeneration involving the removal of the oligonucleotide using one reagent (typically ammonium hydroxide) and then treatment of the support with a second reagent (which may be faster but otherwise damaging to the oligonucleotide product thereby necessitating use of a two-step regeneration) allows flexibility in the choice of capping and regeneration reagents.

The reagent used to effect cleavage is not particularly restricted and is
30 within the purview of a person skilled in the art. Preferably, the reagent is a base mild enough not to damage the oligonucleotide product but sufficiently strong to

-25-

effect rapid cleavage. Non-limiting examples of suitable reagents for this purpose may be selected from the group consisting of ammonium hydroxide, ammonium hydroxide/methanol, ammonia/methanol, ammonium hydroxide/methylamine, potassium carbonate/methanol, *t*-butylamine, ethylenediamine, methylamine, dimethylamine, trimethylamine/water and the like. Cleavage may also be performed under neutral conditions using fluoride ion (i.e. 1M tetrabutylammonium fluoride/THF or triethylamine trihydrofluoride). The reagent used to remove the capping reagent from unreacted sites may consist of the above reagents or other stronger bases such as sodium or potassium hydroxide. In our preferred embodiment, ammonium hydroxide can be used to cleave the oligonucleotide product from the support, remove the HQPD linker arm, and cleave chloroacetyl protected hydroxyl groups in a single regeneration step. The preferred temperature for the cleavage and regeneration is room temperature, but higher or lower temperatures can be employed, subject to the limitations of the apparatus used.

Embodiments of the invention will be illustrated in the following Examples which should not be construed as limiting the scope of the invention. In the Examples, the following materials were used:

1. CPG, long chain alkylamine controlled pore glass, 120-200 mesh, 500Å, 90-120 µmol/g of NH₂ groups), commercially available from CPG Inc. (Lincoln Park, NJ);
2. HQPD, Hydroquinone-O,O'-diacetic acid, commercially available from Lancaster Synthesis Ltd. (Lancashire, England);
3. Ammonium hydroxide solutions (28-30%) and solvents were obtained from VWR Canlab (Edmonton, Alberta, Canada);
4. Cap A, a solution comprising acetic anhydride, 2,6-lutidine and tetrahydrofuran (THF) in a volume ratio of 1:1:8;
5. Cap B, a solution comprising N-methylimidazole and THF in a volume ratio of 16:84;
6. I₂/H₂O oxidation, a solution comprising 0.05M I₂ in THF, H₂O and pyridine in a volume ratio of 7:2:1;

7. Ammonium hydroxide/40% aqueous methylamine (AMA) in a volume ratio of 1:1;
8. Anhydrous pyridine and acetonitrile, distilled from CaH_2 ;
9. Anhydrous methanol, distilled from Mg turnings;
- 5 10. DIEA, diisopropylethylamine, reagent grade;
11. MeCN, acetonitrile, low water DNA synthesis grade;
12. DMAP, 4-dimethylaminopyridine, reagent grade;
13. DEC, 1-(3-dimethylaminopropyl)-ethylcarbodiimide, reagent grade;
- 10 14. HBTU, 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluoro-phosphate, reagent grade;
- 15 15. HATU, *O*-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate, reagent grade;
16. HOAT, 1-hydroxy-7-azabenzotriazole, reagent grade;
- 15 17. tBPA, *t*-butylphenoxyacetic anhydride in THF, obtained from Perseptive Biosystems;
18. HOBT, 1-hydroxybenzotriazole, reagent grade; and
19. TEA, triethylamine, reagent grade.

In the following Examples the amount of nucleoside (loading) on the insoluble supports was determined by spectrophotometric trityl analysis. In this procedure, a sample of support (4-5 mg) was accurately weighed directly into a 10 mL volumetric flask. A solution of dichloroacetic acid in 1,2-dichloroethane in a volume ration of 5:95 was then added to fill the flask. The contents were then thoroughly mixed and the absorbance of the orange coloured solution was measured at 503 nm using a Philips UV/Vis spectrophotometer. The nucleoside loading (in $\mu\text{mol/g}$ of CPG) was then calculated as:

$$\text{Loading} = (A_{503} \times \text{Vol} \times 1000) / (\text{Wt} \times 76)$$

-27-

wherein A_{503} = absorbance at 503 nm, Vol = solution volume in mL, and Wt = amount of CPG tested in mg. The accuracy of the trityl determination was approximately $\pm 2-3\%$.

5 Examples 1-5: Synthesis of 5'-dimethoxytritylnucleoside-3'-O-hemihydroquinone-O,O'-diacetates.

Various HQPD-nucleoside conjugates were prepared using the following general technique:

10 HQPD (10 mmol, 2.26 g), 5'-dimethoxytrityl protected nucleoside (10 mmol), DMAP (1 mmol, 122 mg), DEC (10 mmol, 1.92 g), triethylamine (0.2 mL) and dichloromethane (50 mL) were combined in a 100 mL round bottomed flask and stirred at room temperature overnight. The solution was transferred to a separatory funnel, diluted with additional CH_2Cl_2 (50 mL), washed once with acidified H_2O (150 mL H_2O containing a few drops of 10% aqueous HCl) and
15 several times with H_2O . The CH_2Cl_2 solution was dried over anhydrous MgSO_4 , filtered, and then evaporated to yield the product as a light grey solid wherein B^* and R^9 are as detailed in Table 1.

Table 1

Example	B^*	R^9
1	N^6 -benzoyladenine	H
2	N^4 -benzoylcytosine	H
3	N^2 -isobutyrylguanine	H
4	Thymine	H
5	Uracil	O- <i>t</i> -butyldimethylsilyl

25

The crude material was checked by silica gel TLC (10% methanol/ CHCl_3). The desired nucleoside-HQPD product was the major product ($\text{R}_f \approx 0.04 - 0.13$) with small amounts of starting 5'-dimethoxytrityl protected nucleoside ($\text{R}_f \approx 0.4 - 0.7$) and a byproduct, assumed to be the diester ($\text{R}_f \approx 0.7 -$
30 0.9). The crude material was suitable for attachment to the support and was used without further purification.

Thus, those of skill in the art will recognize that Examples 1-4 relate to the production of an HQPD-deoxyribonucleoside conjugate whereas Example 5 relates to the production of an HQPD-ribonucleoside conjugate.

5 Example 6 - Preparation of N-(1-hydroxyhexyl)-succinic diamide CPG.

CPG (25 g), succinic anhydride (50 mmol, 5 g), DMAP (5 mmol, 610 mg) and anhydrous pyridine (110 mL) were combined in a 250 mL round bottom flask and shaken at room temperature (24 hours). The CPG was then filtered off, washed with methanol then chloroform, and dried.

10 Succinylated CPG (5 g), 6-amino-1-hexanol (1 mmol, 121 mg), DMAP (0.5 mmol, 61 mg), DEC (5 mmol, 958 mg), triethylamine (0.5 mL) and dichloromethane (20 mL) were combined in a 100 mL round bottom flask and shaken at room temperature overnight. Pentachlorophenol (2.5 mmol, 670 mg) was added and the flask was again shaken overnight. Piperidine (25 mL) was
15 added and after shaking for 5 minutes, the CPG was filtered off, washed with methanol then chloroform and dried. To ensure quantitative blocking of all unreacted succinyl groups, the CPG was treated a second time with pentachlorophenol (2.5 mmol, 670 mg), DMAP (0.5 mmol, 61 mg), DEC (5 mmol, 958 mg), triethylamine (0.5 mL) and dichloroethane (20 mL). After
20 shaking at room temperature overnight, piperidine (25 mL) was added and after another 5 minutes, the CPG was filtered off, washed as above and dried.

Examples 7-11: Coupling of HQPD-Nucleoside Conjugates to the
 N-(1-hydroxyhexyl)-Succinic Diamide CPG.

25 In Examples 7-11, the various HQPD-nucleoside conjugates produced in Examples 1-5, respectively, were coupled to the support produced in Example 6 to produce various linker arms within the scope of the present invention.

 The following general procedure was used: hydroxyl derivatized CPG (250 mg), HBTU (0.05 mmol, 19 mg), HOBT (0.05 mmol, 7 mg), and HQPD-nucleoside conjugate (0.05 mmol) were combined in a 4 mL glass vial and sealed
30 with a septum; DIEA (1.5 mmol, 0.26 mL) and anhydrous acetonitrile (1.3 mL)

were added via syringe; the vial was shaken at room temperature for 10 minutes; then the CPG was filtered off, washed with dichloromethane and dried. The nucleoside loading was determined by colorimetric trityl analysis (R. T. Pon in "Methods in Molecular Biology", Vol. 20: Protocols for Oligonucleotides and
 5 Analogs, S. Agrawal, ed., 1993, Humana Press Inc., Totowa, NJ, the contents of which are hereby incorporated by reference) and are reported in Table 2.

Table 2

Example	HQPD-nucleoside conjugate prepared in Example #	Nucleoside Loading ($\mu\text{mol/g}$)
7	1	39.1
8	2	37.7
9	3	23.9
10	4	39.5
11	5	24.2

15
 Examples 12-22: Automated Strategies For Coupling HQPD-Nucleoside Conjugates to the N-(1-Hydroxyhexyl)-Succinic Diamide CPG.

In these Examples, the methodology described in Examples 7-11 was
 20 employed using a Perkin-Elmer Applied Biosystems 394 automated DNA synthesizer. The HQPD-nucleoside conjugate (0.2 M, 1 eq.) with DIEA (2 eq.) and the coupling agent (0.2 M), both in filtered acetonitrile solution, were respectively installed on bottle positions #7 and #8 of the automated synthesizer. Hydroxyl derivatized CPG (prepared in Example 6) was placed into a plastic
 25 synthesis column (~12 mg/column) and installed on column position #1 of the synthesizer. A custom program (begin procedure) was prepared which: (i) washed the column with acetonitrile (4 x 20 sec); (ii) simultaneously delivered solutions from both bottle positions #7 and #8 to fill the synthesis column (4.0 sec); (iii) waited a variable amount of time (0-600 sec) to allow the coupling
 30 reaction to proceed; and (iv) washed the column clean with acetonitrile (4 x 20 sec). The amount of nucleoside loading was determined by colorimetric analysis

-30-

of the trityl colours released by the synthesizer using an unmodified synthesis cycle. The above procedure was used to evaluate the extent and rate of a number of different coupling agents and the results are reported in Table 3.

5 Example 23: Support Recyclability I

In this Example, an initial study was conducted to determine the ability to conduct multiple cycles of nucleoside coupling (as described in Examples 7-11) and cleavage of the HQPD linker using the support described in Example 6.

10 The equipment used in this Example was a model 394 DNA synthesizer commercially available from Perkin-Elmer, Applied Biosystems Division. The synthesizer was custom programmed to achieve simultaneous mixing of a solution (0.2 M) of HQPD-nucleoside conjugate and DIEA (0.4 M) in anhydrous acetonitrile with a solution (0.2 M) of HBTU/HOBT/DIEA in anhydrous acetonitrile followed by a ten minute coupling (wait) step as described in
15 Examples 12-22. Further, the synthesizer was operated to employ a 10 minute cleavage step using an AMA solution with no capping steps.

The nucleoside loading levels on the support for successive cycles of coupling and cleavage using the same HQPD-nucleoside conjugate are reported in Table 4. For clarity, in Table 4, reference is made to Examples 1-4 above for
20 the particular HQPD-nucleoside conjugate used.

Table 3

Example	B*	R ²	Coupling Agent ¹	Nucleoside Loading Level (μmol/g)				
				0 sec ³	60 sec ³	150 sec ³	300 sec ³	600 sec ³
12	T	H	HBTU (alone)	-	14.6	-	35.3	47.1
13	T	H	HBTU/HOBT ²	-	-	-	-	57.7
14	T	H	HBTU/DMAP (1:0.05)	-	28.2	41.6	53.0	63.4
15	T	H	HBTU/DMAP	-	60.1	66.0	67.2	72.2
16	G ^{ibu}	H	HBTU/NMI	-	12.5	-	32.7	35.3
17	G ^{ibu}	H	HBTU/HOBT ²	-	22.0	-	32.2	32.3
18	G ^{ibu}	H	HBTU/DMAP	-	34.1	33.2	32.9	32.3
19	T	H	HBTU/DMAP	26.6	58.7	-	-	-
20	T	H	HATU/HOAT ²	-	19.9	29.6	41.8	50.0
21	T	H	HATU/DMAP	44.0	63.2	67.0	-	-
22	T	H	HATU/NMI	8.6	23.1	-	37.4	43.9

Notes:

¹unless otherwise indicated all reagents are in a 1:1 molar ratio²also includes one equivalent of DIEA.³wait step

Table 4

		Nucleoside Loading Level Using HQPD-Nucleoside			
		Conjugates ($\mu\text{mol/g}$)			
Cycle #	Example 1	Example 2	Example 3	Example 4	
1	50.4	47.5	35.2	33.6	
2	41.2	42.1	30.1	37.3	
3	38.2	38.5	35.3	32.5	
4	35.1	40.4	30.2	39.7	
5	36.2	39.7	29.0	29.6	
6	35.4	37.5	32.0	-	
Average	39.4	41.0	32.0	34.5	

The results reported in Table 4 clearly show that, at least in regard to the initial nucleoside coupled to the support, it is possible to repeatedly cleave off the nucleoside and couple it again to the support in the form of an HQPD-nucleoside conjugate.

Example 24 - Support Recyclability II

In this Example, multiple oligonucleotides were produced using the DNA synthesizer described in Example 23 and the linker arm produced in Example 10 above.

Initially, the linker arm was capped with a mixture of tBPA solution and Cap B reagent (1:1 by volume) for 30 minutes and then packed into three plastic synthesis columns (40-60 mg of support/column). Multiple synthesis columns were used to mitigate any difficulties which might be encountered in manipulating small amounts of the linker arm through the various steps. The synthesis columns were used in parallel on the DNA synthesizer with an unmodified 1 μmol scale synthesis program to prepare a 17-base oligonucleotide.

After synthesis of the desired oligonucleotide, the DNA synthesizer automatically attended to cleavage thereof by contacting the support with ammonium hydroxide for a period of 3 minutes. The oligonucleotide product in

ammonium hydroxide solution was removed for analysis and then the synthesis columns were removed and disassembled. The spent linker arm material from each column was combined and then regenerated by stirring in a solution of AMA for a period of 30 minutes. The cleavage regeneration was done using this two step procedure to avoid exposing the oligonucleotide to the AMA solution. The regenerated support was dried under vacuum and the coupling, capping, oligonucleotide synthesis, cleavage and linker arm regeneration steps were repeated cyclically.

The specific nucleoside loading level obtained from the coupling step (N.L.), the average yield for each of the chain extension steps during the oligonucleotide synthesis (A.Y.), the amount of linker arm used (L.A. Amt.), the oligonucleotide sequence synthesized, and the amount of crude oligonucleotide (Oligo. Yield) produced are reported in Table 5.

As illustrated in Table 5, the present linker arm is capable of being used in cycle steps of: (i) coupling (i.e. to produce the linker arm), (ii) capping, (iii), oligonucleotide synthesis, (iv) oligonucleotide cleavage, and (v) linker arm regeneration.

Example 25: Support Recyclability III

The methodology of Example 16 was repeated except that the duration of the coupling, capping, and regeneration steps was reduced to 10 minutes.

In this Example, six oligonucleotides were successively produced using the same support material. The various process parameters and product properties reported in Example 24 are reported for this Example in Table 6.

Example 26: Support Recyclability IV

In this Example, all the steps involved in a cycle of coupling, capping, oligonucleotide synthesis, cleavage and regeneration were performed by the automated DNA synthesizer to eliminate any manual handling of the solid-phase support.

An 11.8 mg sample of the support prepared in Example 6 was packed into a single plastic synthesis column. Coupling of HQPD-nucleoside conjugates, as prepared in Examples 1-4, was performed in a similar manner as Example 15 using a 150 second coupling time and was followed by a 5 minute capping step using equal volumes of 0.5 M chloroacetic anhydride/2, 6-lutidine in THF and Cap B reagent. The chloroacetic anhydride solution also replaced the Cap A reagent (acetic anhydride) normally used during the oligonucleotide synthesis steps. Otherwise, an unmodified 0.2 μ mol scale synthesis cycle was used for the oligonucleotide synthesis. Cleavage of the oligonucleotide and regeneration of the support was performed simultaneously with a ten minute treatment with ammonium hydroxide (no AMA solution was required). The relevant process parameters and product properties are reported in Table 7.

Examples 27-39: Use of 5'-dimethoxytrityl-2'-deoxyribonucleoside-3'-O-hemisuccinates

In the following Examples, the commercially available nucleosides: N⁶-benzoyl-5'-dimethoxytrityl-2'-deoxyadenosine-3'-O-hemisuccinate; N⁴-benzoyl-5'-dimethoxytrityl-2'-deoxycytidine-3'-O-hemisuccinate; 5'-dimethoxytrityl-N²-isobutyryl-2'-deoxyguanosine-3'-O-hemisuccinate; and 5'-dimethoxytritylthymidine-3'-O-hemisuccinate were evaluated in procedures similar to those outlined in Examples 12, 15, 20 and 21 above. However, in the following Examples, reagent concentrations of either 0.05M or 0.2M were evaluated. Also, because of limited solubility, the 5'-dimethoxytritylthymidine-3'-O-hemisuccinate was dissolved in 1:1 (by volume) dichloromethane:acetonitrile instead of just acetonitrile. The results are reported in Table 8.

The results in Table 8 indicate that nucleosides containing a succinic acid moiety couple less effectively than nucleosides containing an HQPD moiety (e.g. compare Examples 13 and 17 with Example 31) when using the HBTU/HOBT reagent. However, use of HBTU/DMAP or the even more powerful HATU/DMAP reagent can still provide rapid and satisfactory nucleoside loading levels, especially when 0.2 M reagent concentrations are employed.

Table 5

Cycle #	N.L. ($\mu\text{mol/g}$)	A.Y. (%)	L.A. Amt. (mg)	Oligonucleotide Sequence	Oligo. Yield (A_{260} units)
1	39	97.5	180	dGTAAACGACGGCCAGT	599
2	46	98.1	146	dGATTTAGGTGACACTAT	585
3	39	97.9	118	dTGCCTAATGAGTGAGCT	581

Table 6

Cycle #	N.L. ($\mu\text{mol/g}$)	A.Y. (%)	L.A. Amt. (mg)	Oligonucleotide Sequence	Oligo. Yield (A_{260} units)
1	56	97.7	132	dGTAAACGACGGCCAGT	723
2	66	97.6	125	dCTTGGCGTAATCATGGT	747
3	49	98.2	119	dTGCCTAATGAGTGAGCT	622
4	49	98.2	106	dTCTGTGCCAGCTGCATT	503
5	44	97.8	~100	dCCGCTTCCTCGCTCACT	378
6	40	97.0	~100	dGTAAACGACGGCCAGT	275

Table 7

Cycle #	B [*]	N.L. ($\mu\text{mol/g}$)	A.Y. (%)	Oligonucleotide Sequence	Oligo. Yield (A ₂₆₀ units)
1	T	64.7	-	-	-
2	T	53.5	98.2	dGTAAACGACGGCCAGT	62
3	A ^{Bz}	33.1	98.8	dGAGTCGACCTGCAGGCA	41
4	C ^{Bz}	44.3	99.0	dACATACGAGCCGGAAGC	56
5	G ^{tBu}	13.9	99.2	dTGCCCGCTTCCAGTCG	17

-37-

Table 8

Example	B ^a	Conc. (M)	Coupling Agent ¹	Nucleoside Loading Level (μmol/g)			
				60 sec ³	150 sec ³	300 sec ³	600 sec ³
27	A ^{Bz}	0.05	HBTU/DMAP	7.2	-	-	22.9
28	A ^{Bz}	0.05	HATU/DMAP	8.5	-	-	30.0
29	A ^{Bz}	0.05	HBTU/HOBT ²	-	-	-	4.7
30	A ^{Bz}	0.05	HATU/HOAT ¹	-	-	-	5.0
31	A ^{Bz}	0.2	HBTU/HOBT ²	-	-	-	14.7
32	A ^{Bz}	0.2	HBTU/DMAP	26.3	-	-	66.0
33	A ^{Bz}	0.2	HATU/DMAP	38.9	54.3	75.7	89.2
34	C ^{Bz}	0.05	HBTU/DMAP	-	-	-	18.0
35	C ^{Bz}	0.05	HATU/DMAP	-	-	-	30.6
36	G ^{Bu}	0.05	HBTU/DMAP	-	-	-	19.0
37	G ^{Bu}	0.05	HATU/DMAP	9.4	-	-	32.9
38	T	0.05	HBTU/DMAP	-	-	-	10.9
39	T	0.05	HATU/DMAP	-	-	-	18.3

Notes: ¹unless otherwise indicated all reagents are in a 1:1 molar ratio²also includes one equivalent of DIEA.³wait step

SUBSTITUTE SHEET (RULE 26)

- 37A -


Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any
5 other integer or step or group of integers or steps.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161
2162
2163
2164
2165
2166
2167
2168
2169
2170
2171
2172
2173
2174
2175
2176
2177
2178
2179
2180
2181
2182
2183
2184
2185
2186
2187
2188
2189
2190
2191
2192
2193
2194
2195
2196
2197
2198
2199
2200
2201
2202
2203
2204
2205
2206
2207
2208
2209
221

-38-

5 The Claims defining the invention are as follows:

1. A solid support for oligonucleotide synthesis, the solid support having the following formula:



10 wherein: R⁸ is selected from the group consisting of a substituted or unsubstituted C₁-C₂₀ alkyl group, a substituted or unsubstituted C₅-C₃₀ aryl group and a substituted or unsubstituted C₅-C₄₀ alkylaryl group; X³ and X⁴ are the same or differed and are selected from the group consisting of -O-, -S-, -S(O)₂- and -N(R¹²)-; R¹² is selected from the group consisting of a substituted or
 15 unsubstituted C₁-C₂₀ alkyl group, a substituted or unsubstituted C₅-C₃₀ aryl group, a substituted or unsubstituted C₅-C₄₀ alkylaryl group and H; Y is selected from the group consisting of:

20

-CH ₂ -CH ₂ -;	-CH ₂ -;
-CH ₂ -O-CH ₂ -;	-CH ₂ -CH ₂ -CH ₂ -;
-CH=CH-;	-CH=C(CH ₃)-;
-C(CH ₃)=C(CH ₃)-;	-CH ₂ -C(=CH ₂)-; and
-CH ₂ -S-CH ₂ -;	


25 wherein when Y is -CH₂-CH₂-, at least one of X³ and X⁴ is -O-.

2. The solid support defined in claim 1, wherein R⁸ is a substituted or unsubstituted C₁-C₂₀ alkyl group.



-39-

- 5 3. The solid support defined in claim 1, wherein R^8 is a substituted or unsubstituted C_1 - C_{10} alkyl group.
4. The solid support defined in claim 1, wherein R^8 is selected from the group consisting of ethyl, *n*-propyl, *n*-butyl, *n*-pentyl and *n*-hexyl.
- 10 5. The solid support defined in claim 1, wherein X^3 and X^4 are both NR^{12} .
6. The solid support defined in claim 1, wherein Y is $-CH_2-CH_2-$.
- 15 7. The solid support defined in claim 1, wherein SUPPORT is an inorganic substance.
8. The solid support defined in claim 7, wherein the inorganic substance is selected from the group consisting of silica, glass beads, porous glass, aluminosilicates, borosilicates, metal oxides, clays and mixtures thereof.
- 20 9. The solid support defined in claim 1, wherein SUPPORT is an organic substance.
- 25 10. The solid support defined in claim 9, wherein the organic substance is a cross-linked polymer.
11. A linker arm-nucleoside conjugate for solid support oligonucleotide synthesis, the linker arm comprising the following formula:



-40-

- 5 wherein: R^8 is selected from the group consisting of a substituted or unsubstituted C_1 - C_{20} alkyl group, a substituted or unsubstituted C_5 - C_{30} aryl group and a substituted or unsubstituted C_5 - C_{40} alkylaryl group; X^3 and X^4 are the same or differed and are selected from the group consisting of -O-, -S-, -S(O)₂- and -N(R¹²)-; R^{12} is selected from the group consisting of a substituted or
- 10 unsubstituted C_1 - C_{20} alkyl group, a substituted or unsubstituted C_5 - C_{30} aryl group, a substituted or unsubstituted C_5 - C_{40} alkylaryl group and H; Y is selected from the group consisting of:

- 15
- | | |
|--|---|
| -CH ₂ -CH ₂ -; | -CH ₂ -; |
| -CH ₂ -O-CH ₂ -; | -CH ₂ -CH ₂ -CH ₂ -; |
| -CH=CH-; | -CH=C(CH ₃)-; |
| -C(CH ₃)=C(CH ₃)-; | -CH ₂ -C(=CH ₂)-; and |
| -CH ₂ -S-CH ₂ -; | |

- 20 and Z is a linker moiety; wherein when Y is -CH₂-CH₂-, at least one of X^3 and X^4 is -O-.

- 25 12. The linker arm defined in claim 11, wherein R^8 is a substituted or unsubstituted C_1 - C_{20} alkyl group.

13. The linker arm defined in claim 11, wherein R^8 is a substituted or unsubstituted C_1 - C_{10} alkyl group.

- 30 14. The linker arm defined in claim 11, wherein R^8 is selected from the group consisting of ethyl, *n*-propyl, *n*-butyl, *n*-pentyl and *n*-hexyl.


15. The linker arm defined in claim 11, wherein X^3 and X^4 are both NR¹².

16. The linker arm defined in claim 11, wherein Y is -CH₂-CH₂-.




-41-


- 5 17. The linker arm defined in claim 11, wherein Z has the following formula:




18. The linker arm defined in claim 11, wherein Z has the following formula:




19. The linker arm defined in claim 11, wherein Z has the following formula:



20. The linker arm defined in claim 11, wherein Z has the following formula:



- 5 wherein: R^1 , R^2 and R^3 are the same or different and are selected from the group consisting of hydrogen, halide, a substituted or unsubstituted C_1 - C_{20} alkyl group, a substituted or unsubstituted C_5 - C_{30} aryl group and a substituted or unsubstituted C_5 - C_{40} alkylaryl group; R^4 and R^5 are the same or different and are selected from the group consisting of hydrogen, a substituted or unsubstituted C_1 - C_{20} alkyl group, a substituted or unsubstituted C_5 - C_{30} aryl group and a substituted or unsubstituted C_5 - C_{40} alkylaryl group; X^1 is selected from the group consisting of -O-, -S-, -C(O)-, -S(O)₂- and -N(R)-; R is selected from the group comprising hydrogen, a substituted or unsubstituted C_1 - C_{20} alkyl group, a substituted or unsubstituted C_5 - C_{30} aryl group and a substituted or unsubstituted C_5 - C_{40} alkylaryl group; n is 0, 1 or 2; and one of A^1 and B^1 is selected from the group consisting of hydrogen, halide, a substituted or unsubstituted C_1 - C_{20} alkyl group, a substituted or unsubstituted C_5 - C_{30} aryl group and a substituted or unsubstituted C_5 - C_{40} alkylaryl group, and the other of A^1 and B^1 has the formula:



- wherein p is 0 or 1, X^2 is selected from the group consisting of -O-, -S-, -C(O)-, -S(O)₂- and -N(R)-, R is selected from the group comprising hydrogen, a

- 5 substituted or unsubstituted C_1 - C_{20} alkyl group, a substituted or unsubstituted C_5 - C_{30} aryl group and a substituted or unsubstituted C_5 - C_{40} alkylaryl group, R^6 and R^7 are the same or different and are selected from the group consisting of a substituted or unsubstituted C_1 - C_{20} alkyl group, a substituted or unsubstituted C_5 - C_{30} aryl group, a substituted or unsubstituted C_5 - C_{40} alkylaryl group and H, and m is 0, 1 or 2.

21. The linker arm defined in claim 20, wherein B^1 is selected from the group consisting of hydrogen, halide, a substituted or unsubstituted C_1 - C_{20} alkyl group, a substituted or unsubstituted C_5 - C_{30} aryl group and a substituted or unsubstituted C_5 - C_{40} alkylaryl group.


22. The linker arm defined in claim 20, wherein each of R^4 , R^5 , R^6 and R^7 is hydrogen.

23. The linker arm defined in claim 20, wherein each of m and n are 1.

24. The linker arm defined in claim 20, wherein each of R^1 , R^2 and R^3 is hydrogen.

25. The linker arm defined in claim 20, wherein X^1 and X^2 are both -O-.

26. The linker arm defined in claim 11, wherein Z has the following formula:




wherein R^4 , R^5 , R^6 and R^7 are the same or different and are selected from the group consisting of hydrogen, a substituted or unsubstituted C_1 - C_{20} alkyl group,



-44-


- 5 a substituted or unsubstituted C₅-C₃₀ aryl group and a substituted or unsubstituted C₅-C₄₀ alkylaryl group, Y is selected from the group consisting of O, S, SO₂ and O-((CH₂)_l-O)_q, l is an integer less than or equal to 60, q is an integer in the range of 1-1000, n and m are the same or different and are 0, 1 or 2, with the proviso that, when Y is O, at least one of n and m is 2.
- 10
27. The linker arm defined in claim 26, wherein SUPPORT is an inorganic substance.
28. The linker arm defined in claim 27, wherein the inorganic substance is
15 selected from the group consisting of silica, glass beads, porous glass, aluminosilicates, borosilicates, metal oxides, clays and mixtures thereof.
29. The linker arm defined in claim 26, wherein SUPPORT is an organic substance.
- 20
30. The linker arm defined in claim 29, wherein the organic substance is a cross-linked polymer.
31. The linker arm defined in claim 11, wherein NUCLEOSIDE is a moiety
25 selected from one of the following formulae:

-45-



- 5 wherein R^8 and R^{10} are the same or different and are hydrogen or a protecting group, R^9 is hydrogen or $-OR^{11}$ wherein R^{11} is hydrogen or a protecting group, and B^* a nucleic acid base.

32. A process for production of a solid support for oligonucleotide synthesis,
 10 the solid support having the following formula:



- wherein: R^8 is selected from the group consisting of a substituted or unsubstituted C_1 - C_{20} alkyl group, a substituted or unsubstituted C_5 - C_{30} aryl group and a substituted or unsubstituted C_5 - C_{40} alkylaryl group; X^3 and X^4 are the same or
 15 differed and are selected from the group consisting of $-O-$, $-S-$, $-S(O)_2-$ and

-46-


- 5 $-N(R^{12})-$; R^{12} is selected from the group consisting of a substituted or unsubstituted C_1-C_{20} alkyl group, a substituted or unsubstituted C_5-C_{30} aryl group, a substituted or unsubstituted C_5-C_{40} alkylaryl group and H; Y is selected from the group consisting of:

- 10 $-CH_2-CH_2-$; $-CH_2-$;
 $-CH_2-O-CH_2-$; $-CH_2-CH_2-CH_2-$;
 $-CH=CH-$; $-CH=C(CH_3)-$;
 $-C(CH_3)=C(CH_3)-$; $-CH_2-C(=CH_2)-$; and
 $-CH_2-S-CH_2-$;


15

wherein when Y is $-CH_2-CH_2-$, at least one of X^3 and X^4 is $-O-$;


the process comprising the step of reacting together the compounds of Formulae I, II and III:



(I)



(II)



(III)

wherein R^5 , X^3 , X^4 and Y are as defined above.

20

33. The process defined in claim 32, wherein the compounds of Formulae I and II are initially reacted to form a conjugate which is reacted with the compound of Formula III.

25

34. The process defined in claim 32, wherein compounds of Formulae II and III are initially reacted to form a conjugate which is reacted with the compound of Formula I.



-47-

5 35. The process defined in claim 32, wherein R^8 is a substituted or unsubstituted C_1 - C_{20} alkyl group.

36. The process defined in claim 32, wherein R^8 is a substituted or unsubstituted C_1 - C_{10} alkyl group.

10

37. The process defined in claim 32, wherein R^8 is selected from the group consisting of ethyl, *n*-propyl, *n*-butyl, *n*-pentyl and *n*-hexyl.

38. The process defined in claim 32, wherein X^3 and X^4 are both NR^{12} .

15

39. The process defined in claim 32, wherein Y is $-CH_2-CH_2-$.

40. The process defined in claim 32, wherein SUPPORT is an inorganic substance.

20

41. The process defined in claim 40, wherein the inorganic substance is selected from the group consisting of silica, glass beads, porous glass, aluminosilicates, borosilicates, metal oxides, clays and mixtures thereof.

25


42. The process defined in claim 32, wherein SUPPORT is an organic substance.

43. The process defined in claim 42, wherein the organic substance is a cross-linked polymer.

30

44. A process for producing a linker arm for solid support oligonucleotide synthesis, the linker arm comprising the following formula:





- 5 wherein: R^8 is selected from the group consisting of a substituted or unsubstituted $\text{C}_1\text{-C}_{20}$ alkyl group, a substituted or unsubstituted $\text{C}_5\text{-C}_{30}$ aryl group and a substituted or unsubstituted $\text{C}_5\text{-C}_{40}$ alkylaryl group; X^3 and X^4 are the same or different and are selected from the group consisting of $-\text{O}-$, $-\text{S}-$, $-\text{S}(\text{O})_2-$ and $-\text{N}(\text{R}^{12})-$; R^{12} is selected from the group consisting of a substituted or
- 10 unsubstituted $\text{C}_1\text{-C}_{20}$ alkyl group, a substituted or unsubstituted $\text{C}_5\text{-C}_{30}$ aryl group, a substituted or unsubstituted $\text{C}_5\text{-C}_{40}$ alkylaryl group and H; Y is selected from the group consisting of:

- 15
- | | |
|---|---|
| $-\text{CH}_2\text{-CH}_2-$; | $-\text{CH}_2-$; |
| $-\text{CH}_2\text{-O-CH}_2-$; | $-\text{CH}_2\text{-CH}_2\text{-CH}_2-$; |
| $-\text{CH=CH-}$; | $-\text{CH=C}(\text{CH}_3)-$; |
| $-\text{C}(\text{CH}_3)=\text{C}(\text{CH}_3)-$; | $-\text{CH}_2\text{-C(=CH}_2)-$; and |
| $-\text{CH}_2\text{-S-CH}_2-$; | |

- 20 and Z is a linker moiety; wherein when Y is $-\text{CH}_2\text{-CH}_2-$, at least one of X^3 and X^4 is $-\text{O}-$;

the process comprising the step of reacting together the compounds of Formulae IV, V and VI:




-49-

NUCLEOSIDE—OH

HO—Z—OH

(IV)

(V)



(VI)

5 wherein R^8 , X^3 , X^4 , Y and Z are as defined above.

45. The process defined in claim 44, wherein the compounds of Formulae IV and V are initially reacted to form a conjugate which is reacted with the compound of Formula VI.

10

46. The process defined in claim 44, wherein compounds of Formulae V and VI are initially reacted to form a conjugate which is reacted with the compound of Formula IV.

15

47. The process defined in claim 44, wherein R^8 is a substituted or unsubstituted C_1 - C_{20} alkyl group.

48. The process defined in claim 44, wherein R^8 is a substituted or unsubstituted C_1 - C_{10} alkyl group.

20

49. The process defined in claim 44, wherein R^8 is selected from the group consisting of ethyl, *n*-propyl, *n*-butyl, *n*-pentyl and *n*-hexyl.


50. The process defined in claim 44, wherein X^3 and X^4 are both NR^{12} .




5

51. The process defined in claim 44, wherein Y is $-\text{CH}_2-\text{CH}_2-$.


52. The process defined in claim 44, wherein Z has the following formula:



53. The process defined in claim 44, wherein Z has the following formula:




10 54. The process defined in claim 44, wherein Z has the following formula:




55. The process defined in claim 44, wherein Z has the following formula:

-51-



- 5 wherein: R^1 , R^2 and R^3 are the same or different and are selected from the group consisting of hydrogen, halide, a substituted or unsubstituted C_1 - C_{20} alkyl group, a substituted or unsubstituted C_5 - C_{30} aryl group and a substituted or unsubstituted C_5 - C_{40} alkylaryl group; R^4 and R^5 are the same or different and are selected from the group consisting of hydrogen, a substituted or unsubstituted C_1 - C_{20} alkyl group, a substituted or unsubstituted C_5 - C_{30} aryl group and a substituted or unsubstituted C_5 - C_{40} alkylaryl group; X^1 is selected from the group consisting of -O-, -S-, -C(O)-, -S(O)₂- and -N(R)-; R is selected from the group consisting of hydrogen, a substituted or unsubstituted C_1 - C_{20} alkyl group, a substituted or unsubstituted C_5 - C_{30} aryl group and a substituted or unsubstituted C_5 - C_{40} alkylaryl group; n is 0, 1 or 2; and one of A^1 and B^1 is selected from the group consisting of hydrogen, halide, a substituted or unsubstituted C_1 - C_{20} alkyl group, a substituted or unsubstituted C_5 - C_{30} aryl group and a substituted or unsubstituted C_5 - C_{40} alkylaryl group, and the other of A^1 and B^1 has the formula:



- wherein p is 0 or 1, X^2 is selected from the group consisting of -O-, -S-, -C(O)-, -S(O)₂- and -N(R)-, R is selected hydrogen, a substituted or unsubstituted C_1 - C_{20}

-52-

5 alkyl group, a substituted or unsubstituted C₅-C₃₀ aryl group and a substituted or unsubstituted C₅-C₄₀ alkylaryl group, R⁶ and R⁷ are the same or different and are selected from the group consisting of a substituted or unsubstituted C₁-C₂₀ alkyl group, a substituted or unsubstituted C₅-C₃₀ aryl group and a substituted or unsubstituted C₅-C₄₀ alkylaryl group, and m is 0, 1 or 2.

10

56. The process defined in claim 55, wherein B¹ is selected from the group consisting of hydrogen, halide, a substituted or unsubstituted C₁-C₂₀ alkyl group, a substituted or unsubstituted C₅-C₃₀ aryl group and a substituted or unsubstituted C₅-C₄₀ alkylaryl group.

15

57. The process defined in claim 44, wherein each of R⁴, R⁵, R⁶ and R⁷ is hydrogen.

58. The process defined in claim 44, wherein each of m and n is 1.


20

59. The process defined in claim 44, wherein each of R¹, R² and R³ is hydrogen.

60. The process defined in claim 44, wherein X¹ and X² are both -O-.

25

61. The process defined in claim 44, wherein Z has the following formula:




wherein R⁴, R⁵, R⁶ and R⁷ are the same or different and are selected from the group consisting of hydrogen, a substituted or unsubstituted C₁-C₂₀ alkyl group, a substituted or unsubstituted C₅-C₃₀ aryl group and a substituted or unsubstituted

-53-

- 5 C₃-C₄₀ alkylaryl group, Y is selected from the group consisting of -O-, -S-,
-S(O)₂- and -O-((CH₂)_l-O)_q-, l is an integer less than or equal to 60, q is an integer
in the range of 1-1000, n and m are the same or different and are 0, 1 or 2, with
the proviso that, when Y is O, at least one of n and m is 2.
- 10 62. The process defined in claim 44, wherein SUPPORT is an inorganic
substance.
63. The process defined in claim 62, wherein the inorganic substance is
selected from the group consisting of silica, glass beads, porous glass,
15 aluminosilicates, borosilicates, metal oxides, clays and mixtures thereof.
64. The process defined in claim 44, wherein SUPPORT is an organic
substance.
- 20 65. The process defined in claim 64, wherein the organic substance is a cross-
linked polymer.
66. The process defined in claim 44, wherein NUCLEOSIDE is a moiety
selected from one of the following formulae:

25

-54-



- 5 wherein R^8 and R^{10} are the same or different and are hydrogen or a protecting group, R^9 is hydrogen or $-OR^{11}$ wherein R^{11} is hydrogen or a protecting group, and B^* is a nucleic acid base.

67. A solid support for oligonucleotide synthesis and a process for
10 preparing same as hereinbefore described with reference to the examples.

DATED THIS 22nd day of August, 2000.

University Technologies International, Inc.

15 By Its Patent Attorneys

DAVIES COLLISON CAVE





2/2




FIGURE 2